Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
Home Editorial Board Current Issue Special Issue Archives Indexing Submit Article
Instruction to Authors Manuscript Charges Copyright Form Model Manuscript Process Flow (Time Frame) FAQ
Reviewer Guidelines Selection of Reviewers Join our Team of Reviewers Apply as Reviewer Reviewer Login
Editorial Review Policy Embargo Policy Ethical Expectations Consent For Identifying Information Informed Consent Manuscript Withdrawal Policy Peer Review Process Plagiarism Policy Ethical Violations Appeal Policy Against Editorial Decision Advertising Policies Authorship Policy
Access Policies Authorship Publication Policy Publication Ethics Complaints Policy Confidential Information Conflicts of Interest Policy Consent for Copyrighted Material Copyright Policy Corrections and Retractions Digital Preservation Policy Research On Human And Animal Studies Open Access Policy
Publication Ethics Contact
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2020) [Effective from January 1, 2020] For more details click here

Join as a Reviewer

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2020)
[Effective from January 1, 2020]
For more details click here
ICV 2023: 95.56
Index Copernicus ICI Journals Master List 2023 - IJCMAS--ICV 2023: 95.56
For more details click here
Announcement

See Guidelines to Authors
Current Issues
Download Publication Certificate

Original Research Articles                      Volume : 14, Issue:11, November, 2025
PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com /
submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2018: 95.39
NAAS RATING 2020: 5.38
Metrics and citations

Int.J.Curr.Microbiol.App.Sci.2025.14(11): 297-304
DOI: https://doi.org/10.20546/ijcmas.2025.1411.030


Maldi - TOF and Vitek-2 Compact - A Revolutionary Tools For Rapid Diagnosis and Antifungal Susceptibility Tests for Clinically Isolated Candida
Richa Agrawal, Sanju Pannu, Ravindra Singh Rathore, Swati Duggal, Praveen Rathore and Prabhu Prakash*
Department of Microbiology, Dr. S. N. Medical College Jodhpur, India
*Corresponding author
Abstract:

Candida species are common fungal commensals in humans but can cause a spectrum of infections collectively known as candidiasis, ranging from superficial mucocutaneous disease to life-threatening invasive infections, particularly in immunocompromised individuals. In recent years, the epidemiology of candidemia has shifted, with non-albicans Candida (NAC) species such as C. tropicalis, C. glabrata, C. parapsilosis, and C. krusei being increasingly reported. Rapid and accurate species identification is essential, and MALDI-TOF MS has emerged as a powerful tool by generating species-specific protein spectra. This cross-sectional, hospital-based study was conducted from February to May 2025. Clinical specimens including blood, urine, CSF, pus, sputum, endotracheal aspirates, and bronchoalveolar lavage were processed using Hichrome Candida agar, MALDI-TOF MS, and the VITEK 2 Compact system. Of 400 samples analyzed, 74 (18.5%) yielded Candida isolates. The highest positivity was observed in sputum (29.72%), followed by urine and ETA (20.27% each). Candida albicans was the predominant species (62.16%), followed by C. tropicalis (29.72%). Less frequent species included C. kefyr and C. glabrata (2.7% each). Amphotericin B showed high susceptibility across species, while fluconazole resistance was notable in C. albicans (30%). MALDI-TOF MS is crucial for timely species-level identification and supports targeted antifungal therapy, especially amid rising NAC prevalence and antifungal resistance.


Keywords: Candida albicans; Non-albicans Candida; Candidiasis; MALDI-TOF MS

References:
  1. Al Salmi 1, Metry AM, Al Ismaili F. Hola A, Al Riyami M, Khamis F. et al., Transplant tourism and invasive fungal infection. Int J Infect Dis. 2018 Apr 69: 120-9. https://doi.org/10.1016/j.ijid.2018.01.029
  2. Antifungal susceptibility and speciation of clinical isolates of Candida at Tertiary Care Cospital, Central IndiaGade, N. et al., International Journal of Infectious Diseases, Volume 101, 394
  3. Banerjee S, Denning DW, Chakrabarti A. One Health aspects & priority roadmap for fungal diseases: A mini-review. Indian J Med Res. 2021 Mar, 153(3): 311-9 https://doi.org/10.4103/ijmr.IJMR_768_21
  4. Chander J. textbook of medical mycology. 4th New delhi: Mehta publisher; 2008 ASDCV.
  5. Christina Tsui, Eric F. Kong, Mary Ann Jabra-Rizk, Pathogenesis of Candida albicans biofilm, Pathogens and Disease, Volume 74, Issue 4, June 2016, ftw018 https://doi.org/10.1093/femspd/ftw018
  6. Gajdács M, Dóczi I, Ábrók M, Lázár A, Burián K. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent European J Urol. 2019; 72(2): 209-214. https://doi.org/10.5173/ceju.2019.1909
  7. Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses. 2016 Apr; 59(4): 198-219.
  8. Hoenigl M, Gangneux JP, Segal E, Alanio A, Chakrabarti A, Chen SCA, et al., Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: New leadership is about working together. Mycoses. 2018 Nov; 61(11): 885-94
  9. K, Shetty AK, Antony B. MALDI-TOF MS Analysis to Detect the Prevalence of Non-albicans Candidemia with a Special Emphasis on Candida auris from a Tertiary Care Centre in Coastal Karnataka. Online J Health Allied Scs. 2024; 23(2): 9
  10. Kaur R, Dhakad MS, Goyal R, Haque A, Mukhopadhyay G. Identification and Antifungal Susceptibility Testing of CandidaSpecies: A Comparison of Vitek-2 System with Conventional and Molecular Methods. J Glob Infect Dis. 2016 Oct-Dec; 8(4): 139-146. https://doi.org/10.4103/0974-777X.192969. PMID: 27942193; PMCID: PMC5126752.
  11. Lee H, Choi SH, Oh J, Koo J, Lee HJ, Cho S, Shin JH, Lee HK, Kim S, Lee CH, Kim YR, Sohn Y, Kim WJ, Ryu SW, Sung G, Kim J, 2022. Comparison of Six Antifungal Susceptibilities of 11 Candida Species Using the VITEK2 AST–YS08 Card and Broth Microdilution Method. Microbiol Spectr 10: e01253-21.
  12. Lopes, J. P., & Lionakis, M. S. (2021). Pathogenesis and virulence of Candida albicans. Virulence, 13(1), 89–121.
  13. M A, JD J. Species Distribution and Antifungal Susceptibility Patterns of Candida Isolates: A Cross-Sectional Study from a Tertiary Care Hospital in South India. Cureus 2025 Feb; 17(2): e79666
  14. Makled, A.F., Ali, S.A.M., Labeeb, A.Z. et al., Characterization of Candidaspecies isolated from clinical specimens: insights into virulence traits, antifungal resistance and molecular profiles. BMC Microbiol 24, 388 (2024) https://doi.org/10.1186/s12866-024-03515-x
  15. Malani AN, Kauffman CA. Candida urinary tract infections: treatment options. Expert Rev Anti Infect Ther. 2007 Apr, 5(2): 277-84.
  16. Mathur P, Hasan F, Singh PK, Malhotra R, Walia K, Chowdhary A. Five-year profile of candidaemia at an Indian trauma centre: High rates of Candida auris blood stream infections. Mycoses. 2018 Sep; 61(9): 674-80.
  17. Medina N, Soto-Debrán JC, Seidel D, Akyar I, Badali H, Barac A, et al., MixIn Yeast: A Multicenter Study on Mixed Yeast Infections. J Fungi (Basel). 2020 Dec 29; 7(1): 13.
  18. Nandini D, Manonmoney J, Lavanya J, Leela KV, Sujith. A Study on Prevalence and Characterization of Candida Species in Immunocompromised Patients. J Pure Appl Microbiol.2021; 15(4): 2065-2072.
  19. Rajni E, Chaudhary P, Garg VK, Sharma R, Malik M. A complete clinico-epidemiological and microbiological profile of candidemia cases in a tertiary-care hospital in Western India. Antimicrobe Steward Healthcare Epidemiolgy. 2022 Mar 7; 2(1): e37
  20. Samantaray S, Singh R. Evaluation of MALDI-TOF MS for Identification of Species in the Candida parapsilosis Complex from Candidiasis Cases. J Appl Lab Med. 2022 Jun 30; 7(4): 889-900
  21. Siopi M, Pachoulis I, Leventaki S, Spruijtenburg B, Meis JF, Pournaras S, Vrioni G, Tsakris A, Meletiadis J. 2024. Evaluation of the Vitek 2 system for antifungal susceptibility testing of Candida auris using a representative international panel of clinical isolates: overestimation of amphotericin B resistance and underestimation of fluconazole resistance. J Clin Microbiol 62: e01528-23.
  22. Tajane SB, Pawar S, Patil S. Revisiting the History of Candidiasis. Cureus. 2025 Feb 11; 17(2): e78878
  23. Thean Yen Tan, Li Yang Hsu, Marissa M. Alejandria, Romanee Chaiwarith, Terrence Chinniah, Methee Chayakulkeeree, Saugata Choudhury, Yen Hsu Chen, Jong Hee Shin, Pattarachai Kiratisin, Myrna Mendoza, Kavitha Prabhu, Khuanchai Supparatpinyo, Ai Ling Tan, Xuan Thi Phan, Thi Thanh Nga Tran, Gia Binh Nguyen, Mai Phuong Doan, Van An Huynh, Su Minh Tuyet Nguyen, Thanh Binh Tran, Hung Van Pham, Antifungal susceptibility of invasive Candidabloodstream isolates from the Asia-Pacific region, Medical Mycology, Volume 54, Issue 5, July 2016, Pages 471–477, 
  24. Thomas-Rüddel DO, Schlattmann P, Pletz M, Kurzai O, Bloos F. Risk Factors for Invasive Candida Infection in Critically III Patients: A Systematic Review and Meta-analysis. Chest. 2022 Feb; 161(2): 345-55.
  25. Tiwari, K., & Verma, A. K. (2020). Antifungal susceptibility pattern of clinical isolates of Candida from a tertiary care hospital in Chhattisgarh, India. Research Gate.
  26. Utler, G., Rasmussen, M., Lin, M. et al.,Evolution of pathogenicity and sexual reproduction in eight Candida Nature 459,657(2009)
  27. Yaguchi T, Tanaka R. [Classification and phylogeny of pathogenic fungi]. Nihon Rinsho. 2008 Dec; 66(12): 2261-7
Download this article as Download

How to cite this article:

Richa Agrawal, Sanju Pannu, Ravindra Singh Rathore, Swati Duggal, Praveen Rathore and Prabhu Prakash. 2025. Maldi - TOF and Vitek -2 Compact - A Revolutionary Tools for Rapid Diagnosis and Antifungal Susceptibility Tests For Clinically Isolated Candida.Int.J.Curr.Microbiol.App.Sci. 14(11): 297-304. doi: https://doi.org/10.20546/ijcmas.2025.1411.030
Copyright: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike license.

Citations
Home | Terms of Use | Copyright Form 2012-2020 Copy rights reserved IJCMAS. Powered by ThinkNEXT Technologies